Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2-specific immune responses after two versus three doses of COVID-19 vaccination in end-stage renal disease patients and kidney transplant recipients
TCTR20210524002Phase 4Completed
- Sponsor
- Faculty of Medicine Ramathibodi Hospital, Mahidol University
- Start
- Aug 2021
- Countries
- 1
01
Overview
Phase 4 trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Faculty of Medicine Ramathibodi Hospital, Mahidol University. Primary endpoints: SARS-CoV-2-specific immune response after two doses and SARS-CoV-2-specific immune response after three doses. Started Aug 2021; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210524002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210524002.